Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) Return on Invested Capital (2018 - 2021)

Historic Return on Invested Capital for Celldex Therapeutics (CLDX) over the last 3 years, with Q4 2021 value amounting to 0.16%.

  • Celldex Therapeutics' Return on Invested Capital rose 1200.0% to 0.16% in Q4 2021 from the same period last year, while for Dec 2021 it was 0.16%, marking a year-over-year increase of 1200.0%. This contributed to the annual value of 0.23% for FY2021, which is 1800.0% up from last year.
  • Celldex Therapeutics' Return on Invested Capital amounted to 0.16% in Q4 2021, which was up 1200.0% from 0.24% recorded in Q3 2021.
  • In the past 5 years, Celldex Therapeutics' Return on Invested Capital registered a high of 0.16% during Q4 2021, and its lowest value of 1.29% during Q2 2018.
  • For the 3-year period, Celldex Therapeutics' Return on Invested Capital averaged around 0.61%, with its median value being 0.29% (2020).
  • The largest annual percentage gain for Celldex Therapeutics' Return on Invested Capital in the last 5 years was 1200bps (2021), contrasted with its biggest fall of -200bps (2021).
  • Quarter analysis of 3 years shows Celldex Therapeutics' Return on Invested Capital stood at 1.23% in 2018, then soared by 77bps to 0.28% in 2020, then surged by 42bps to 0.16% in 2021.
  • Its Return on Invested Capital was 0.16% in Q4 2021, compared to 0.24% in Q3 2021 and 0.28% in Q4 2020.